In order to directly target B cells and plasma cells residing in the GALT with the intent to directly inhibit Gd-IgA1 production, targeted-release-formulation (TRF) budesonide (nefecon) was developed.

花旗发表报告指，与云顶新耀举行了最新会议，管理层指导2025年销售额为14亿元，包括Nefecon的10亿元和Xerava的4亿元。而Nefecon已成功纳入国家医保。

Corticosteroids are first-line drugs for the treatment of UC but also cause adverse side effects. Budesonide (BUD), a corticosteroid with relatively low side effects, has been approved by the Food and ...